BioSpace News Archive

Neuronetics, Inc. announced its financial and operating results for the fourth quarter and full year of 2019.

BioArctic AB announced that the company’s partner Eisai will include Swedish clinics in the confirmatory Phase 3 study of the drug candidate BAN2401.

Expands specialty diagnostics portfolio with attractive molecular diagnostics capabilities, including infectious disease testing

Itamar Medical Ltd., a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders, reported unaudited financial results for the three-month period and year ended December 31, 2019.

Novartis Pharmaceuticals Canada Inc. is pleased to announce that Health Canada has approved MayzentTM for the treatment of adults with secondary progressive multiple sclerosis with active disease evidenced by relapses or imaging features characteristic of multiple sclerosis inflammatory activity, to delay the progression of physical disability.

Richard Twomey, President and CEO of Mölnlycke, will after six years leave the organisation.

ADMA Biologics (“ADMA”), today announced that it has received another Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent application related to its intellectual property portfolio encompassing immunoglobulin plasma pool compositions used in the manufacturing of ASCENIV™

Obsidian Therapeutics, a biotechnology company pioneering controllable cell and gene therapies, today announced the appointment of Anders Götzsche to its Board of Directors

As part of the preparations for a potential offering of American Depository Shares in the United States and a concurrent listing on the Nasdaq Global Market in the United States, the extraordinary general meeting resolved to, in accordance with the board of directors’ proposal, authorize the board of directors to, at one or several occasions and for the period up until the next annual general meeting

Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation for elamipretide for the treatment of Barth syndrome, an ultra-rare genetic condition.